ISSN: 1301-2193 E-ISSN: 1308-9846
  • Turkish Journal of
    Endocrinology and Metabolism

Development of Hypocalcemia Due to Targeted Therapies
Hedefe Yönelik Tedavilere Bağlı Gelişen Hipokalsemi
Received Date : 17 Jul 2019
Accepted Date : 10 Dec 2019
Available Online : 20 Jan 2020
Ankara University Faculty of Medicine, Department of Endocrinology and Metabolism, Ankara, Turkey
Doi: 10.25179/tjem.2019-70737 - Makale Dili: EN
Turk J Endocrinol Metab 2020;24:105-108
ABSTRACT
Novel biological agents are available for the treatment of malignancies, and apart from their utility, they may also have several side effects. The effects on the endocrine system are frequently observed, among which thyroid dysfunctions are common and well-characterized, whereas parathyroid dysfunctions are rare and not well characterized. Herein, we describe two of our patients that displayed hypoparathyroidism and were treated with epidermal growth factor receptor (EGFR) inhibitor erlotinib, vascular endothelial growth factor receptor, and EGFR inhibitor vandetanib.
ÖZET
Malignitelerin tedavisinde kullanılmakta olan yeni biyolojik ajanların yararlarının yanı sıra, birtakım yan etkileri de mevcuttur. Endokrin sistem üzerine sıklıkla etkiler görülmektedir ve bu etkiler arasında tiroid disfonksiyonu en sık olan ve en iyi tanımlanmış etki iken; paratiroid disfonksiyonu nadirdir ve iyi tanımlanamamıştır. Burada, epidermal büyüme faktörü reseptörü (EBFR) inhibitörü erlotinib ve hem vasküler endotelyal büyüme faktör reseptörü hem EBFR inhibitörü olan vandetanib ile tedavi edilen 2 olgumuzda gelişen hipoparatiroidizm tablosunu tanımladık.
Kaynaklar
  1. Foley J, Nickerson N, Riese DJ, 2nd, Hollenhorst PC, Lorch G, Foley AM. At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone. Odontology. 2012;100:109-129. [Crossref]  [PubMed]  [PMC] 
  2. Lodish MB. Clinical review: kinase inhibitors: adverse effects related to the endocrine system. J Clin Endocrinol Metab. 2013;98:1333-1342. [Crossref]  [PubMed]  [PMC] 
  3. Cozzolino M, Lu Y, Sato T, Yang J, Suarez IG, Brancaccio D, Slatopolsky E, Dusso AS. A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. Am J Physiol Renal Physiol. 2005;289:F1096-1102. [Crossref]  [PubMed] 
  4. Arcidiacono MV, Sato T, Alvarez-Hernandez D, Yang J, Tokumoto M, Gonzalez-Suarez I, Lu Y, Tominaga Y, Cannata-Andia J, Slatopolsky E, Dusso AS. EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. J Am Soc Nephrol. 2008;19:310-320. [Crossref]  [PubMed]  [PMC] 
  5. Arcidiacono MV, Cozzolino M, Spiegel N, Tokumoto M, Yang J, Lu Y, Sato T, Lomonte C, Basile C, Slatopolsky E, Dusso AS. Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism. J Am Soc Nephrol. 2008;19:1919-1928. [Crossref]  [PubMed]  [PMC] 
  6. Dimke H, van der Wijst J, Alexander TR, Meijer IM, Mulder GM, van Goor H, Tejpar S, Hoenderop JG, Bindels RJ. Effects of the EGFR inhibitor erlotinib on magnesium handling. J Am Soc Nephrol. 2010;21:1309-1316. [Crossref]  [PubMed]  [PMC] 
  7. Lorch G, Gilmore JL, Koltz PF, Gonterman RM, Laughner R, Lewis DA, Konger RL, Nadella KS, Toribio RE, Rosol TJ, Foley J. Inhibition of epidermal growth factor receptor signaling reduces hypercalcemia induced by human lung squamous-cell carcinoma in athymic mice. Br J Cancer. 2007;97:183-193. [Crossref]  [PubMed]  [PMC] 
  8. Rosen LS, Goldman JW, Algazi AP, Turner PK, Moser B, Hu T, Wang XA, Tuttle J, Wacheck V, Wooldridge JE, Banck M. A first-in-human phase i study of a bivalent MET antibody, emibetuzumab (LY2875358), as monotherapy and in combination with erlotinib in advanced cancer. Clin Cancer Res. 2017;23:1910-1919. [Crossref]  [PubMed] 
  9. Thornton K, Kim G, Maher VE, Chattopadhyay S, Tang S, Moon YJ, Song P, Marathe A, Balakrishnan S, Zhu H, Garnett C, Liu Q, Booth B, Gehrke B, Dorsam R, Verbois L, Ghosh D, Wilson W, Duan J, Sarker H, Miksinski SP, Skarupa L, Ibrahim A, Justice R, Murgo A, Pazdur R. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2012;18:3722-3730. [Crossref]  [PubMed]